Endovascular Today (ISSN 1551-1944 print and ISSN 2689-792X online) is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the ...

Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral. Analyst Price Forecast Suggests 14.00% Downside As of December 23, 2024, ...

Inari shareholders are getting a fair price ... with a primary focus on stroke and aneurysm treatment including coils, catheters, microcatheters, stents, and mechanical thrombectomy devices.

In this article, we are going to take a look at where Inari Medical, Inc. (NASDAQ:NARI) stands against other firms post strong gains amid Wall Street bloodbath. Wall Street’s main indices closed ...

Fintel reports that on January 7, 2025, Wells Fargo downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 14.20% Downside As of ...

The deal for Bolt Medical is the second big medtech acquisition unveiled this week, following Stryker’s $4.9 billion purchase of Inari Medical on Monday ... acoustic pressure waves inside of a balloon ...

Canaccord downgraded Inari Medical (NARI) to Hold from Buy with a price target of $80, up from $74, after Stryker (SYK) entered into a definitive agreement to acquire Inari in cash for $80 per share.

Inari, based in Irvine, California, makes a variety of devices including catheter-based mechanical thrombectomy systems to treat vascular disease. Stryker, which has a larger orthopedics business, ...

About Inari Medical, Inc., iRhythm Technologies and Inc. Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific ...

Drug Delivery From ATK to BTK: What Is on the Horizon? With moderator Ramon L. Varcoe, MBBS, MS, FRACS, PhD, MMed(ClinEpi), and panelists Marianne Brodmann, MD; Osamu ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...